MarsBio Management

NAPIGEN is a biotechnology company focused on genome editing, specifically in mitochondrial engineering. The company develops innovative solutions aimed at enhancing food supply by creating hybrid crop plants with significantly improved yields. By producing robust male sterile lines, NAPIGEN offers advantages over traditional lines, ensuring stability and elite genetic backgrounds. This technology facilitates the development of non-GM hybrid seeds for crops that are primarily non-hybrid, such as wheat. Additionally, NAPIGEN's expertise extends to the genome engineering of various organisms, including plants, microbes, and animals, by targeting mitochondria and chloroplasts, which are essential for energy production in cells. The company's advancements are designed to meet societal needs and promote public acceptance of its biotechnological innovations.

Karma Biotechnologies, Inc. develops therapies for autoimmune diseases. It offers Xavines, a therapeutic to treat autoimmunity, allergies, and food sensitivities. Karma Biotechnologies, Inc. was incorporated in 2019 and is based in Los Angeles, California.

Spira is a company focused on producing algae-based ingredients that aim to replace petroleum and animal-derived compounds, promoting sustainability. By utilizing cyanobacteria, Spira develops industrial ingredients that serve various sectors, including beverages, cosmetics, textiles, and confectionery. The company collaborates with a global network of farming partners to manufacture raw materials that not only reduce reliance on petrochemicals but also support carbon capture and wastewater management efforts. Additionally, Spira's initiatives assist farmers in developing countries, contributing to a transition towards healthier materials and more sustainable practices across industries.